{"id":"oros-methylphenidate-mph","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Decreased appetite"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Nervousness"},{"rate":"5","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate blocks the reuptake transporters for dopamine and norepinephrine, increasing their synaptic concentrations and enhancing neurotransmission in the prefrontal cortex and striatum. The OROS (osmotic release oral system) delivery mechanism provides controlled, extended release of the drug over approximately 12 hours, maintaining therapeutic levels throughout the day. This sustained-release formulation improves compliance and provides more consistent symptom control compared to immediate-release formulations.","oneSentence":"OROS-Methylphenidate is an extended-release formulation of methylphenidate that inhibits the reuptake of dopamine and norepinephrine in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:00.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT05842330","phase":"PHASE3","title":"Benefits of ADHD Treatment in Detained People","status":"RECRUITING","sponsor":"Stéphanie Baggio","startDate":"2024-01-01","conditions":"ADHD","enrollment":150},{"nctId":"NCT02293655","phase":"PHASE4","title":"The Effects of ADHD Medication (TEAM) Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-01-12","conditions":"ADHD","enrollment":204},{"nctId":"NCT04507204","phase":"PHASE4","title":"Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2020-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT05410626","phase":"NA","title":"The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-06-01","conditions":"Adhd","enrollment":78},{"nctId":"NCT00916786","phase":"","title":"Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-08-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":240},{"nctId":"NCT00763971","phase":"PHASE3","title":"Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2008-11-17","conditions":"ADHD","enrollment":336},{"nctId":"NCT01552902","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-03","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":549},{"nctId":"NCT01552915","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-17","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":464},{"nctId":"NCT01727414","phase":"PHASE4","title":"Attention Deficit Disorder Medication Response Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2006-06","conditions":"ADHD - Inattentive Type, ADHD - Combined Type","enrollment":171},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT00516269","phase":"PHASE3","title":"Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-08","conditions":"Breast Cancer, Fatigue, Gastrointestinal Cancer","enrollment":42},{"nctId":"NCT01853280","phase":"PHASE2, PHASE3","title":"L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":47},{"nctId":"NCT01109849","phase":"PHASE3","title":"Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth","status":"COMPLETED","sponsor":"Florida International University","startDate":"2010-11","conditions":"ADHD, Growth","enrollment":230},{"nctId":"NCT00603434","phase":"PHASE1","title":"Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-01","conditions":"Methamphetamine Dependence, Methamphetamine Abuse","enrollment":16},{"nctId":"NCT00302458","phase":"PHASE4","title":"A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT00550147","phase":"PHASE2","title":"Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2004-02","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":30},{"nctId":"NCT02352051","phase":"PHASE4","title":"Effects of Atx and Oros-mph on Executive Functions","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2014-02","conditions":"Executive Dysfunction","enrollment":43},{"nctId":"NCT01933880","phase":"PHASE4","title":"A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2009-12","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":194},{"nctId":"NCT02215538","phase":"PHASE2, PHASE3","title":"OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD","status":"COMPLETED","sponsor":"University of Utah","startDate":"2004-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":47},{"nctId":"NCT00714688","phase":"PHASE3","title":"A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2008-02","conditions":"Attention Deficit/ Hyperactivity Disorder","enrollment":279},{"nctId":"NCT00307684","phase":"PHASE3","title":"Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2006-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":155},{"nctId":"NCT00758160","phase":"PHASE4","title":"The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":296},{"nctId":"NCT01533493","phase":"NA","title":"Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)","enrollment":33},{"nctId":"NCT01012622","phase":"PHASE4","title":"An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":142},{"nctId":"NCT00302393","phase":"PHASE3","title":"Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-06","conditions":"Healthy","enrollment":20},{"nctId":"NCT00889915","phase":"PHASE4","title":"Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-04","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":228},{"nctId":"NCT01060150","phase":"PHASE4","title":"An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":115},{"nctId":"NCT00323947","phase":"PHASE4","title":"Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2003-05","conditions":"Attention Deficit Disorder With Hyperactivity, Epilepsy","enrollment":33},{"nctId":"NCT00937040","phase":"PHASE4","title":"Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2009-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":357},{"nctId":"NCT00264797","phase":"PHASE3","title":"Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2006-02","conditions":"ADHD, Substance Abuse","enrollment":303},{"nctId":"NCT00181714","phase":"PHASE4","title":"Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-11","conditions":"ADHD","enrollment":203},{"nctId":"NCT00880217","phase":"PHASE2","title":"A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":430},{"nctId":"NCT01127646","phase":"PHASE4","title":"A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":23},{"nctId":"NCT00585910","phase":"PHASE4","title":"Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-01","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":94},{"nctId":"NCT00253747","phase":"PHASE3","title":"Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2005-11","conditions":"ADHD, Smoking","enrollment":255},{"nctId":"NCT00593112","phase":"PHASE4","title":"Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-11","conditions":"ADHD","enrollment":39},{"nctId":"NCT00931398","phase":"PHASE4","title":"Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2010-04","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":""},{"nctId":"NCT00778310","phase":"PHASE4","title":"Neuroimaging of the Effects of Concerta in the Treatment of ADHD","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2008-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":76},{"nctId":"NCT00598182","phase":"","title":"Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":64},{"nctId":"NCT00246207","phase":"PHASE3","title":"CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2005-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":32},{"nctId":"NCT00530257","phase":"PHASE4","title":"Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":30},{"nctId":"NCT00757029","phase":"PHASE4","title":"Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2005-10","conditions":"Attention Deficit Disorder With Hyperactivity, Methylphenidate, Pharmacogenetics","enrollment":150},{"nctId":"NCT01065259","phase":"PHASE4","title":"Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children","status":"COMPLETED","sponsor":"Peking University","startDate":"2008-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":262},{"nctId":"NCT00302354","phase":"PHASE4","title":"A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-12","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT00302367","phase":"PHASE4","title":"An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-01","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT00302406","phase":"PHASE4","title":"Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":50},{"nctId":"NCT00301639","phase":"PHASE3","title":"A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-03","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT00269776","phase":"PHASE3","title":"An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1998-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269815","phase":"PHASE3","title":"Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269802","phase":"PHASE3","title":"A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269789","phase":"PHASE3","title":"A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1998-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00246220","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2005-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":402},{"nctId":"NCT00304681","phase":"PHASE3","title":"An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":147},{"nctId":"NCT00549640","phase":"PHASE2","title":"Testing Methylphenidate for Smoking Abstinence","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-01","conditions":"Smoking","enrollment":80},{"nctId":"NCT01130467","phase":"","title":"Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-09","conditions":"Attention Deficit Disorders With Hyperactivity, Attention Deficit Disorder, Hyperkinetic Syndrome","enrollment":150},{"nctId":"NCT00482313","phase":"PHASE3","title":"Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Psychiatry Karolinska","startDate":"2007-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":30},{"nctId":"NCT00518232","phase":"PHASE4","title":"A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2006-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":520},{"nctId":"NCT00862108","phase":"PHASE4","title":"Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2008-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":50},{"nctId":"NCT00842127","phase":"PHASE4","title":"Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)","status":"COMPLETED","sponsor":"Bundang CHA Hospital","startDate":"2006-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":150},{"nctId":"NCT00663442","phase":"PHASE4","title":"Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"1999-12","conditions":"ADHD","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Concerta"],"phase":"marketed","status":"active","brandName":"OROS-Methylphenidate (MPH)","genericName":"OROS-Methylphenidate (MPH)","companyName":"Children's Hospital Medical Center, Cincinnati","companyId":"children-s-hospital-medical-center-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OROS-Methylphenidate is an extended-release formulation of methylphenidate that inhibits the reuptake of dopamine and norepinephrine in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}